Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Atezolizumab: First Global Approval.

Literature DB >> 27412122

Atezolizumab: First Global Approval.

Abstract

Atezolizumab (Tecentriq™)-a monoclonal antibody targeting programmed death ligand 1 (PD-L1 or CD274 antigen)-is being developed by Genentech as treatment for a variety of haematological malignancies and solid tumours. It been approved in the US as a second-line therapy for urothelial carcinoma and is awaiting approval as a second-line therapy for non-small cell lung cancer. This article summarizes the milestones in the development of atezolizumab leading to this first approval for urothelial carcinoma.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2016 PMID： 27412122 DOI： 10.1007/s40265-016-0618-8

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

4 in total

1. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

Authors: David F McDermott; Jeffrey A Sosman; Mario Sznol; Christophe Massard; Michael S Gordon; Omid Hamid; John D Powderly; Jeffrey R Infante; Marcella Fassò; Yan V Wang; Wei Zou; Priti S Hegde; Gregg D Fine; Thomas Powles
Journal: J Clin Oncol Date: 2016-01-11 Impact factor: 44.544

2. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors: Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal: Nature Date: 2014-11-27 Impact factor: 49.962

3. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors: Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal: Lancet Date: 2016-03-04 Impact factor: 79.321

4. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Authors: Louis Fehrenbacher; Alexander Spira; Marcus Ballinger; Marcin Kowanetz; Johan Vansteenkiste; Julien Mazieres; Keunchil Park; David Smith; Angel Artal-Cortes; Conrad Lewanski; Fadi Braiteh; Daniel Waterkamp; Pei He; Wei Zou; Daniel S Chen; Jing Yi; Alan Sandler; Achim Rittmeyer
Journal: Lancet Date: 2016-03-10 Impact factor: 79.321

4 in total

28 in total

Review 1. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors: Kenneth M Felsenstein; Dan Theodorescu
Journal: Nat Rev Urol Date: 2017-11-14 Impact factor: 14.432

2. Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.

Authors: Kun Fang; Guoqiang Dong; Yu Li; Shipeng He; Ying Wu; Shanchao Wu; Wei Wang; Chunquan Sheng
Journal: ACS Med Chem Lett Date: 2018-03-26 Impact factor: 4.345

Review 3. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors: Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal: J Hematol Oncol Date: 2022-10-08 Impact factor: 23.168

4. The terminal sialic acid of stage-specific embryonic antigen-4 has a crucial role in binding to a cancer-targeting antibody.

Authors: Caroline Soliman; Jia Xin Chua; Mireille Vankemmelbeke; Richard S McIntosh; Andrew J Guy; Ian Spendlove; Lindy G Durrant; Paul A Ramsland
Journal: J Biol Chem Date: 2019-12-12 Impact factor: 5.157

Atezolizumab: First Global Approval.

1. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

2. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

3. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

4. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Review 1. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

2. Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.

Review 3. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

4. The terminal sialic acid of stage-specific embryonic antigen-4 has a crucial role in binding to a cancer-targeting antibody.

Review 5. Polysaccharide-based nanomedicines for cancer immunotherapy: A review.

Review 6. Emerging immunological strategies: recent advances and future directions.

Review 7. Clinical translation of immunomodulatory therapeutics.

Review 8. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.

Review 9. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.

Review 10. A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma.